OPM announces Protocol Submission for its Phase 1b/2a Study

OPM announces Protocol Submission for its Phase 1b/2a Study, REVERT for OPM-101 in Combination with Pembrolizumab in Patients
with Advanced Melanoma Resistant to Anti-PD1

Dijon (France), March 24, 2025, 6:00 pm CET – Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker: ALOPM), a clinical-stage company developing innovative therapies to overcome immune evasion and drug resistance, today announced the submission to Swiss authorities of the study protocol for its Phase 1b/2a clinical trial REVERT (RIPK2 for rEsistant  and adVanced mElanoma tReatmenT) with OPM-101, its RIPK2 inhibitor in advanced melanoma patients with resistance to anti-PD-1. This submission of the study protocol follows the announcement of positive results from the Phase 1 study in October 2024.